NASDAQ:SVRA - Savara Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.67
  • Forecasted Upside: 264.58 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.28
+0.30 (1.20%)

This chart shows the closing price for SVRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Savara Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SVRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SVRA

Analyst Price Target is $4.67
▲ +264.58% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Savara in the last 3 months. The average price target is $4.67, with a high forecast of $7.00 and a low forecast of $3.00. The average price target represents a 264.58% upside from the last price of $1.28.

This chart shows the closing price for SVRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Savara. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/9/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2021HC WainwrightReiterated RatingBuyLow
3/16/2021Piper SandlerInitiated CoverageOverweight$7.00High
3/15/2021OppenheimerInitiated CoverageOutperform$4.00High
12/15/2020HC WainwrightLower Price TargetBuy$6.00 ➝ $3.00High
11/23/2020Evercore ISIInitiated CoverageOutperformMedium
3/17/2020HC WainwrightReiterated RatingBuyHigh
12/20/2019HC WainwrightReiterated RatingBuy$6.00High
10/3/2019LADENBURG THALM/SH SHReiterated RatingHold$1.00Low
8/12/2019Evercore ISISet Price TargetBuy$17.00Medium
6/13/2019Canaccord GenuityLower Price TargetBuy$22.00 ➝ $15.00N/A
6/13/2019HC WainwrightLower Price TargetBuy ➝ Buy$22.00 ➝ $6.00N/A
6/13/2019LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$21.00 ➝ $3.00N/A
6/13/2019JMP SecuritiesDowngradeOutperform ➝ Market Perform$2.60N/A
5/14/2019Roth CapitalSet Price TargetHold$10.00High
5/10/2019LADENBURG THALM/SH SHReiterated RatingBuyHigh
4/1/2019LADENBURG THALM/SH SHReiterated RatingBuy$21.00High
3/25/2019Canaccord GenuitySet Price TargetBuy$22.00High
12/20/2018HC WainwrightReiterated RatingBuy$22.00High
11/8/2018HC WainwrightReiterated RatingBuyN/A
8/14/2018Canaccord GenuitySet Price TargetBuy$25.00Low
8/13/2018Roth CapitalInitiated CoverageNeutral$12.00Low
8/10/2018HC WainwrightReiterated RatingBuy$22.00High
8/3/2018HC WainwrightReiterated RatingBuy$22.00Low
8/2/2018Canaccord GenuitySet Price TargetBuy$25.00Low
6/8/2018Evercore ISIInitiated CoverageOutperform$40.00High
5/25/2018HC WainwrightInitiated CoverageBuy$22.00High
5/10/2018Canaccord GenuityReiterated RatingBuyHigh
4/9/2018Canaccord GenuitySet Price TargetBuy$25.00High
2/16/2018Canaccord GenuitySet Price TargetBuy$25.00Low
1/3/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$35.00Medium
10/31/2017Roth CapitalLower Price TargetBuy$40.00 ➝ $32.00N/A
10/30/2017Canaccord GenuityBoost Price TargetBuy$18.00 ➝ $25.00N/A
9/27/2017Roth CapitalReiterated RatingBuy ➝ Buy$40.00Medium
9/22/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$20.00High
9/11/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$20.00High
7/17/2017Canaccord GenuityReiterated RatingBuy$18.00High
6/7/2017Canaccord GenuityInitiated CoverageBuy$18.00High
(Data available from 8/2/2016 forward)
Savara logo
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Read More

Today's Range

Now: $1.28
Low: $1.25
High: $1.31

50 Day Range

MA: $1.62
Low: $1.28
High: $1.89

52 Week Range

Now: $1.28
Low: $1.00
High: $3.58

Volume

243,368 shs

Average Volume

2,466,723 shs

Market Capitalization

$145.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Savara?

The following Wall Street research analysts have issued reports on Savara in the last twelve months: Evercore ISI, HC Wainwright, Oppenheimer Holdings Inc., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for SVRA.

What is the current price target for Savara?

3 Wall Street analysts have set twelve-month price targets for Savara in the last year. Their average twelve-month price target is $4.67, suggesting a possible upside of 264.6%. Piper Sandler has the highest price target set, predicting SVRA will reach $7.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for Savara in the next year.
View the latest price targets for SVRA.

What is the current consensus analyst rating for Savara?

Savara currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SVRA will outperform the market and that investors should add to their positions of Savara.
View the latest ratings for SVRA.

What other companies compete with Savara?

How do I contact Savara's investor relations team?

Savara's physical mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The company's listed phone number is 512-614-1848 and its investor relations email address is [email protected] The official website for Savara is www.savarapharma.com.